Polymer-Free Biolimus A9-Coated Stent Demonstrates More Sustained Intimal Inhibition, Improved Healing, and Reduced Inflammation Compared With a Polymer-Coated Sirolimus-Eluting Cypher Stent in a Porcine Model
Authors:
Open Access
- 1 April 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 3 (2) , 174-183
Abstract
Background— Drug-eluting stents effectively reduce restenosis but may increase late thrombosis and delayed restenosis. Persistent polymer, the drug, or a combination of both could be responsible. Local delivery of Biolimus A9, a rapamycin derivative, from a polymer-free BioFreedom stent (Biosensors International) may prevent these complications.Keywords
This publication has 28 references indexed in Scilit:
- The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: The NOBORI PK studyCatheterization and Cardiovascular Interventions, 2008
- Pathology of Drug-Eluting Stents in HumansJACC, 2006
- Incomplete Neointimal Coverage of Sirolimus-Eluting StentsJACC, 2006
- Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary modelCardiovascular Research, 2004
- Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting StentCirculation, 2004
- Inhibition of Restenosis With a Paclitaxel-Eluting, Polymer-Free Coronary StentCirculation, 2004
- Drug eluting stents: are human and animal studies comparable?Heart, 2003
- Drug-Eluting Stents in Preclinical StudiesCirculation, 2002
- Granulomatous ‘foreign body reactions’ contribute to exaggerated in-stent restenosisCoronary Artery Disease, 1999
- Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine modelJACC, 1992